HanAll Biopharma Co., Ltd. has signed an exclusive licensing deal with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.

This agreement expands the relationship between the companies, which began in 2022 when HanAll made an initial investment in Turn Bio. The terms grant HanAll the right to utilize Turn Bio's Epigenetic Reprogramming of Aging (ERATM) technology to research, develop, manufacture, and commercialize medicines for ophthalmic and otic disease.

HanAll anticipates leveraging synergies between ophthalmic and otic fields where it has therapeutic expertise and experience and drawing on Turn Bio's knowledge of cellular reprogramming, mRNAs, and lipid nanoparticles.

Aging mitigation and cell reprogramming technologies have been gaining attention for their potential to address the high unmet needs in age-related disorders, particularly in the eye and ear. HanAll has been actively exploring cell reprogramming through open collaborations and a global network.

The ERATM technology developed by Turn Bio reverses certain aspects of cellular aging by utilizing a cocktail of mRNA transcription factors specifically designed for transient epigenetic reprogramming. Past attempts at similar technologies have struggled due to the risk of cells differentiating into unforeseen cell types. Turn Bio's technology aims to overcome these challenges by restoring youthful cell function through precise dosing and timing of ERATM while maintaining the original cellular identity, offering promising potential for addressing age-related disorders. Currently, Turn Bio is undertaking pre-clinical research for dermatology and immunology applications.

"We're excited to advance into a new phase of development with Turn Bio to explore the potential of its innovative platform in addressing important age-related conditions. This partnership will enhance HanAll's R&D capabilities in mRNA and LNP product development while also providing an opportunity to explore the potential for pipeline expansion," said Sean Jeong, MD, MBA, CEO of HanAll Biopharma.

"This agreement is a testament to the vast opportunities ahead globally as the world's population grows older," said Anja Krammer, CEO, Turn Bio.

"HanAll's commitment is recognition that our innovative ERA™ technology has the potential to revolutionize treatments for myriad conditions associated with aging," Krammer added.

The deal, valued at over USD 300 million for the first product, is structured around negotiated milestones.